Copyright
©The Author(s) 2021.
World J Diabetes. Feb 15, 2021; 12(2): 138-148
Published online Feb 15, 2021. doi: 10.4239/wjd.v12.i2.138
Published online Feb 15, 2021. doi: 10.4239/wjd.v12.i2.138
Healthy controls (n = 118) | DM | P value | |||
NDR (n = 57) | NPDR (n = 64) | PDR (n = 61) | |||
Baseline characteristics | |||||
Gender (male, %) | 56 (48.70) | 27 (47.37) | 26 (40.63) | 29 (47.54) | 0.947 |
Age (yr) | 59.84 ± 9.60 | 58.21 ± 7.75 | 60.89 ± 9.93 | 65.72 ± 8.36 | < 0.001 |
BMI (kg/m2) | 26.11 ± 3.18 | 27.39 ± 3.71 | 26.86 ± 2.76 | 25.93 ± 3.89 | 0.047 |
SBP (mmHg) | 123.53 ± 14.47 | 126.82 ± 17.62 | 131.66 ± 10.63 | 136.34 ± 11.87 | < 0.001 |
DBP (mmHg) | 73.97 ± 12.08 | 73.54 ± 12.69 | 81.14 ± 15.42 | 77.52 ± 13.09 | 0.0019 |
MAP (mmHg) | 90.49 ± 9.41 | 91.30 ± 10.86 | 97.98 ± 10.78 | 97.13 ± 10.04 | < 0.001 |
Disease information | |||||
Diabetes duration (yr) | - | 5.72 ± 2.64 | 10.92 ± 6.01 | 12.52 ± 4.96 | < 0.001 |
Fasting blood glucose (mg/dL) | 84.73 ± 23.85 | 133.81 ± 24.98 | 143.28 ± 36.25 | 167.86 ± 40.42 | < 0.001 |
HbA1C (%) | 5.87 ± 1.32 | 7.85 ± 1.69 | 8.61 ± 2.11 | 9.27 ± 1.80 | < 0.001 |
Use of oral hypoglycemic agents | - | 38 (66.67) | 50 (78.13) | 44 (72.13) | 0.369 |
Use of insulin | - | 15 (26.31) | 24 (37.50) | 21 (34.43) | 0.408 |
Hypertension (n, %) | 52 (44.07) | 25 (43.86) | 38 (59.38) | 41 (67.21) | 0.009 |
Smoking (n, %) | 37 (31.36) | 14 (24.56) | 18 (28.13) | 19 (31.15) | 0.801 |
Drinking (n, %) | 41 (34.75) | 20 (30.09) | 19 (29.69) | 24 (39.34) | 0.730 |
Laboratory data | |||||
Triglycerides (mmol/L) | 4.70 ± 1.50 | 4.79 ± 1.28 | 4.55 ± 1.28 | 4.88 ± 1.20 | 0.567 |
Total cholesterol (mmol/L) | 4.57 ± 1.54 | 5.01 ± 1.64 | 4.25 ± 1.77 | 4.77 ± 1.79 | 0.077 |
LDL cholesterol (mmol/L) | 3.12 ± 1.12 | 2.96 ± 1.20 | 2.98 ± 1.09 | 2.87 ± 0.94 | 0.504 |
HDL cholesterol (mmol/L) | 1.18 ± 0.27 | 1.14 ± 0.26 | 1.19 ± 0.29 | 1.16 ± 0.28 | 0.740 |
Total bilirubin (mmol/L) | 12.79 ± 3.34 | 13.44 ± 3.89 | 11.55 ± 4.04 | 11.21 ± 3.89 | 0.002 |
AST (U/L) | 21.76 ± 9.08 | 22.62 ± 9.15 | 22.38 ± 8.78 | 22.40 ± 9.60 | 0.930 |
ALT (U/L) | 21.16 ± 8.66 | 22.78 ± 9.35 | 23.16 ± 8.92 | 22.61 ± 8.33 | 0.4251 |
DR | PDR | |||
Multivariate OR (95%CI) | P value | Multivariate OR (95%CI) | P value | |
Age (10 yr) | 0.03 (0.008 to 0.063) | 0.134 | 0.939 (0.003 to 0.011) | 0.005 |
Diabetes duration(1 yr) | 0.032 (0.025 to 0.039) | < 0.001 | 0.007 (0.007 to 0.023) | 0.002 |
Hypertension | -0.023 (-0.105 to 0.059) | 0.577 | 0.015 (-0.129 to 0.022) | < 0.001 |
BMI | -0.008 (-0.019 to 0.001) | 0.090 | -0.053 (-0.023 to -0.001) | 0.166 |
Smoking | -0.033 (-0.109 to 0.044) | 0.402 | -0.012 (-0.098 to 0.075) | 0.032 |
Drinking | -0.023 (-0.096 to 0.050) | 0.532 | -0.012 (-0.143 to 0.021) | 0.791 |
FBG (mg/dL) | 0.002 (0.001 to 0.003) | < 0.001 | -0.061 (0.001 to 0.004) | 0.143 |
HbA1C (%) | 0.017 (-0.002 to 0.036) | 0.084 | 0.002 (-0.006 to 0.037) | < 0.001 |
Total bilirubin (mmol/L) | 0.004 (-0.006 to 0.014) | 0.428 | 0.015 (-0.016 to 0.006) | 0.158 |
Melatonin (pg/mL) | -0.008 (-0.010 to -0.005) | < 0.001 | -0.005 (-0.004 to 0.002) | 0.412 |
Baseline information and laboratory data | Plasma melatonin concentrations | |
r | P value | |
Age | -0.1018 | 0.078 |
Gender | -0.1428 | 0.013 |
Diabetes duration | -0.5623 | < 0.001 |
SBP | -0.2224 | < 0.001 |
DBP | -0.1326 | 0.022 |
MAP | -0.2146 | < 0.001 |
Hypertension | 0.1429 | 0.013 |
BMI | -0.09046 | 0.118 |
Smoking | -0.0543 | 0.349 |
Drinking | -0.06159 | 0.288 |
FBG (mg/dL) | -0.464 | < 0.001 |
HbA1C (%) | -0.481 | < 0.001 |
Triglycerides (mmol/L) | 0.04224 | 0.466 |
Total cholesterol (mmol/L) | 0.01544 | 0.790 |
LDL cholesterol (mmol/L) | 0.02813 | 0.628 |
HDL cholesterol (mmol/L | -0.01587 | 0.784 |
Total bilirubin (mmol/L) | 0.4386 | < 0.001 |
AST (U/L) | -0.06536 | 0.259 |
ALT (U/L) | -0.06815 | 0.239 |
- Citation: Wan WC, Long Y, Wan WW, Liu HZ, Zhang HH, Zhu W. Plasma melatonin levels in patients with diabetic retinopathy secondary to type 2 diabetes. World J Diabetes 2021; 12(2): 138-148
- URL: https://www.wjgnet.com/1948-9358/full/v12/i2/138.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i2.138